{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012381","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.696242+00:00","generated_at":"2026-06-24T21:57:44.825579+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target","bullets":["Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.","Fate receives research funding through Sep 2024 and is eligible for an option exercise fee, milestones, and tiered royalties.","Fate retains global manufacturing rights and the right to co-develop and co-commercialize in the US and Europe.","First iPSC-derived CAR T-cell product candidate targeting solid tumors is advancing toward clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012381","json":"https://secwatch.observer/filing/0000950170-22-012381.json","markdown":"https://secwatch.observer/filing/0000950170-22-012381.md","text":"https://secwatch.observer/filing/0000950170-22-012381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/0000950170-22-012381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/fate-20220628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:57:44.825579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}